Top 6 Companies in the Saxagliptin Market

Saxagliptin is an oral anti-diabetic drug that is used to manage type 2 diabetes. As a DPP-4 inhibitor, it helps increase insulin production and reduce blood sugar levels. The drug is marketed under brand names like Onglyza and is often prescribed alongside diet and exercise. The generic versions of this drug are also manufactured by pharmaceutical companies globally and approved by the FDA.

The saxagliptin market is significantly driven by the rising prevalence of type-2 diabetes. Estimated by the International Diabetes Federation, about 537 million adults (20-79 years) live with diabetes, with 95% having type-2 diabetes. It is also projected that 1 in 8 adults will be living with diabetes by 2045, expected to reach 643 million by 2030 and grow to 783 million by 2045, resulting in the increased demand for effective treatments. Additionally, 240 million people remain undiagnosed, further expanding the potential patient pool. The high burden in low- and middle-income countries, where 75% of adults with diabetes reside, further fuels market growth, driving the need for affordable generic alternatives.

The market development is highly influenced by the increasing FDA approvals for generic versions, making treatments more accessible. The rising health awareness and government initiatives targeting early diagnosis are also shaping the market. Due to the rising prevalence of diabetes globally, pharmaceutical companies are focusing on innovative formulations and combination therapies. Additionally, the demand for oral anti-diabetic drugs like saxagliptin is increasing due to their ease of use over insulin injections. These trends indicate a strong market expansion in the coming years.

Major Companies Shaping the Global Saxagliptin Market in 2025

1.    AstraZeneca

AstraZeneca is a leading global biopharmaceutical company, specialising in developing medicines in oncology, cardiovascular, and diabetes care. AstraZeneca plays a critical role in the saxagliptin market, primarily through its branded drug, Onglyza. For instance, in June 2024, AstraZeneca's Farxiga (Dapagliflozin) received FDA approval to improve glycemic control in children aged 10 years and older with type 2 diabetes, highlighting its ongoing commitment to diabetes management. The company's research and approvals continue to shape the treatment landscape for type 2 diabetes, solidifying its leadership in the market.

2.    Aurobindo Pharma Limited

Aurobindo Pharma Limited is a major global pharmaceutical manufacturer with a robust portfolio of generics, including treatments for diabetes. The company has expanded its role in the saxagliptin market by offering a generic version. For instance, in July 2023, Aurobindo Pharma received final approval from the U.S. FDA for its Abbreviated New Drug Application for saxagliptin tablets. These tablets are an AB-rated generic equivalent of Onglyza, manufactured by AstraZeneca. This approval positions Aurobindo as a significant player in providing affordable treatment options for type 2 diabetes.

3.    Dr. Reddy’s Laboratories Ltd

Dr. Reddy's Laboratories is a leading global pharmaceutical company. It focuses on the development and manufacture of generic medications, biosimilars, and active pharmaceutical ingredients (APIs). In the saxagliptin market, Dr. Reddy’s plays a key role by offering cost-effective generic versions of the drug, enabling broader access to treatment for type 2 diabetes. The company is also involved in ongoing research to expand its portfolio.

4.    Glenmark Pharmaceuticals Inc.

Glenmark Pharmaceuticals is a global pharmaceutical company known for its generics and active pharmaceutical ingredients (APIs). Glenmark has made significant strides in the market by providing generic alternatives to the branded drug Onglyza. For instance, in February 2023, Glenmark Pharmaceuticals Inc. USA received a second tentative approval from the U.S. FDA for saxagliptin tablets, 2.5 mg and 5 mg. These tablets are a generic version of Onglyza, AstraZeneca's brand. The approval of Glenmark’s saxagliptin ensures broader access to type 2 diabetes treatment, reinforcing the company's role in improving global diabetes care.

5.    Kavya Pharma

Kavya Pharma is a pharmaceutical company, known for its manufacturing of a wide range of generic formulations. The company’s involvement in the saxagliptin market is centered on providing affordable alternatives for diabetes management. While it may not be as prominent as larger pharma giants, Kavya Pharma contributes by making saxagliptin available at competitive prices, particularly in developing regions where access to branded drugs is limited.

6.    Lupin

Lupin is a dominating player in the diabetes market, including saxagliptin. For instance, in January 2024, Lupin received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Dapagliflozin and saxagliptin tablets. This approval allowed Lupin to market a generic version of AstraZeneca’s Qtern® tablets. Dapagliflozin and saxagliptin tablets, in combination, are used as adjuncts to diet and exercise to manage type 2 diabetes. Lupin’s ongoing research and approvals underline its role in improving treatment access for diabetes patients globally.

7.    Wellona Pharma

Wellona Pharma, headquartered in India, is a growing pharmaceutical company that manufactures and markets a variety of generic medicines. The company has an expanding presence in the diabetes care segment, including saxagliptin. In the saxagliptin market, Wellona Pharma plays a significant role by offering affordable generic options, helping to reduce the financial burden of type 2 diabetes treatment for patients in various global markets.